CADETS Act

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.